Lv1
100 积分 2021-07-22 加入
Alteplase for Posterior Circulation Ischemic Stroke at 4.5 to 24 Hours
22天前
已完结
Short-Term Safety and Effectiveness for Tenecteplase and Alteplase in Acute Ischemic Stroke
1个月前
已完结
Tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE): A multicentre, prospective, randomized, open-label, blinded-endpoint, controlled phase III non-inferiority trial protocol
1个月前
已完结
Tenecteplase Thrombolysis for Stroke up to 24 Hours After Onset With Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial
1个月前
已完结
Tenecteplase Thrombolysis for Stroke up to 24 Hours After Onset With Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial
1个月前
已完结
Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update
9个月前
已完结
Association of Time to Thrombolysis With Early Reperfusion After Alteplase and Tenecteplase in Patients With Large Vessel Occlusion
1年前
已完结
Safety and Efficacy of Reteplase Versus Alteplase for Acute Ischemic Stroke: A Phase 2 Randomized Controlled Trial
1年前
已完结
Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection
1年前
已完结
STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment–Elevation Myocardial Infarction: A Randomized, Open-Label Trial
1年前
已完结
Very low dose spironolactone protects experimentally-induced polycystic ovarian syndrome from insulin-resistant metabolic disturbances by suppressing elevated circulating testosterone
皖公网安备34019202002308
